Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

Several current immunotherapy approaches target private neoantigens derived from
mutations that are unique to individual patients' tumors. However, immunotherapeutic …

Conventional genome engineering with CRISPR–Cas9 creates double-strand breaks
(DSBs) that lead to undesirable byproducts and reduce product purity. Here we report an …

Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled
by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and …

BACKGROUND Chimeric antigen receptor (CAR) T cell immunotherapy has resulted in
complete remission (CR) and durable response in highly refractory patients. However …

Genetically engineered T cell immunotherapies have provided remarkable clinical success
to treat B cell acute lymphoblastic leukaemia by harnessing a patient's own T cells to kill …

Transposons are mobile genetic elements evolved to execute highly efficient integration of
their genes into the genomes of their host cells. These natural DNA transfer vehicles have …

The clinical success stories of chimeric antigen receptor (CAR)-T cell therapy against B-cell
malignancies have contributed to immunotherapy being at the forefront of cancer therapy …

Allogeneic CD19-specific chimeric antigen receptor (CAR) T cells with inactivated donor T
cell receptor (TCR) expression can be used as an" off-the-shelf" therapeutic modality for …

Chimeric antigen receptor (CAR) technology and its application to regulatory T cells (Tregs)
has garnered interest among researchers in the field of cell and gene therapy. Merging the …